POSFREA

Peak

palonosetron

NDAINTRAVENOUSSOLUTION
Approved
Mar 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

5-HT 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT 3 receptors are located…

Clinical Trials (5)

NCT03097588Phase 2Completed

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Started Apr 2017
43 enrolled
Malignant Neoplasm
NCT02532634Phase 4Completed

Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone

Started Aug 2015
292 enrolled
CancerTumors
NCT01054456Phase 2Completed

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

Started Oct 2009
36 enrolled
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
NCT02635828Phase 4Completed

Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis

Started Oct 2009
40 enrolled
Postoperative Nausea and Vomiting
NCT00903396Phase 2Terminated

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Started Sep 2009
7 enrolled
Anal CancerCarcinoma of the AppendixColorectal Cancer+9 more